SNMMI Curriculum VL

Early Initiation of Lu177 PSMA Radioligand Therapy Prolongs Survival in Metastatic PCa - Harshad Kulkarni

Details
Where in this treatment regimen would you place lutetium-177-PSMA radioligand therapy? This was the question Harshad Kulkarni, MD posed to the audience at the start of his presentation. The aim of the study which he was presenting during this Society of Nuclear Medicine and Molecular Imaging presentation was to determine the influence of timing of lutetium PSMA radioligand therapy in metastatic pr...

Initial Experience with Actinium- 225 PSMA in Advanced Prostate Cancer - Machaba Michael Sathekge

Details
Mike Machaba Sathekge, MD, PhD presents on the power of medicine, specifically targeted radionuclide therapies and the use of actinium-225 in advanced prostate cancer. Targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. He discusses the initial experience with 225Ac-PSMA-617 in a deve...

Prognostic Value of Baseline Imaging Parameters Prior to LuPSMA Therapy - Justin Ferdindandus

Details
At the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual conference, Justin Ferdindandus presents the results of a study which evaluated whether baseline imaging can provide prognostic information in patients treated with lutetium PSMA regarding overall survival and progression-free survival. The post-hoc analysis revealed that a favorable response by the means of a 50% PSA d...

Radium 223 Dichloride Use in Patients with Castrate Resistant Prostate Cancer - Hossein Jadvar

Details
Hossein Jadvar joins Phillip Koo for the last in its series of video presentations in the Society of Nuclear Medicine SNMMI video lecture series. Dr. Jadvar presents on the topic of Radium 223 dichloride use in patients with castrate-resistant prostate cancer. (Length of Interview: 34 min) Biographies: Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer...

SNMMI Osseous Scintigraphy - Ephraim E. Parent

Details
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) presents the Prostate Cancer Imaging and Therapy curriculum. In this continuing education session, Dr. Ephraim Parent joins Dr. Phil Koo to present and discuss bone imaging and the role in prostate cancer, specifically bone scintigraphy. His presentation outlines an overview of Radiopharmaceuticals that are used for bone imaging, planar...

Case-based Approaches: PSMA and Personalized Prostate Cancer Care - Frankis Almaguel

Details
Frankis Almaguel, MD joins Phillip Koo, MD for the ongoing lecture series that is sponsored by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Dr. Almaguel speaks to therapeutic interventions based on Prostate-specific membrane antigen (PSMA) findings that have the potential of changing the treatment of prostate cancer and the impact of personalized care in this disease space. Frank...

Bombesin - A New Frontier for Prostate Cancer Imaging - Andrei Iagaru

Details
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) presents the Prostate Cancer Imaging and Therapy curriculum. Dr. Andrei Iagaru presents the state of development of Gastrin-Releasing Peptide Receptors as Targets for Imaging in Prostate Cancer. He and Phil Koo, MD then discuss the clinical development of Bombesin in the imaging of prostate cancer. Biographies: Andrei H. Iagaru, MD, FAC...

PSMA Theranostics and Personalized Prostate Cancer Care- Frankis Almaguel

Details
Frankis Almaguel, MD joins Phillip Koo, MD for the ongoing lecture series that is sponsored by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Dr. Almaguel speaks to the current state of PSMA theranostics in the care of patients with prostate cancer. Molecular imaging is dependent on biomarkers. These biomarkers are the key to identifying cancer cells within the normal tissue. Preci...

PET C-11 Choline Imaging in Prostate Cancer Patients with Biochemical Recurrence- Ajit H. Goenka

Details
Phillip Koo, MD hosts a lecture in the core curriculum which is developed by the Prostate Cancer Outreach Working Group of the SNMMI. The Prostate Cancer Working Group focuses on increasing awareness of oncologists, urologists and family practitioners about imaging and therapy technologies such as FACBC, bone scintigraphy, and radium-223. This lecture series will cover the complete spectrum of pro...

18F-fluciclovine PET/CT in Patients with Suspected Recurrent Prostate Cancer - Bital Savir-Baruch

Details
Phillip Koo welcomes Bital Savir-Baruch who is presenting a review of prostate cancer imaging with 18F-FACBC fluciclovine (Axumin®) in men with suspected prostate cancer recurrence. Dr. Baruch reviews the benefits of this technology including earlier detection of recurrent disease as compared to conventional imaging, inability of the tracer to be metabolized and the slow urinary excretion. While d...